Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).

Singh RB, Amare Kadam PS.

Urol Oncol. 2013 Oct;31(7):1333-42. doi: 10.1016/j.urolonc.2011.08.012. Epub 2011 Oct 1.

PMID:
21962529
2.

Oxygen sensing, homeostasis, and disease.

Semenza GL.

N Engl J Med. 2011 Aug 11;365(6):537-47. doi: 10.1056/NEJMra1011165. Review. No abstract available. Erratum in: N Engl J Med. 2011 Sep 8;365(10):968.

PMID:
21830968
3.

Developmentally arrested structures preceding cerebellar tumors in von Hippel-Lindau disease.

Shively SB, Falke EA, Li J, Tran MG, Thompson ER, Maxwell PH, Roessler E, Oldfield EH, Lonser RR, Vortmeyer AO.

Mod Pathol. 2011 Aug;24(8):1023-30. doi: 10.1038/modpathol.2011.61. Epub 2011 Apr 15.

4.

von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage.

Roe JS, Kim HR, Hwang IY, Cho EJ, Youn HD.

Oncogene. 2011 Jul 14;30(28):3127-38. doi: 10.1038/onc.2011.40. Epub 2011 Feb 28.

PMID:
21358672
5.

2'-hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma.

Nagaprashantha LD, Vatsyayan R, Singhal J, Lelsani P, Prokai L, Awasthi S, Singhal SS.

Carcinogenesis. 2011 Apr;32(4):568-75. doi: 10.1093/carcin/bgr021. Epub 2011 Feb 8.

6.

Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.

Duignan IJ, Corcoran E, Pennello A, Plym MJ, Amatulli M, Claros N, Iacolina M, Youssoufian H, Witte L, Samakoglu S, Schwartz J, Surguladze D, Tonra JR.

Neoplasia. 2011 Jan;13(1):49-59.

7.

Vhl is required for normal pancreatic β cell function and the maintenance of β cell mass with age in mice.

Choi D, Cai EP, Schroer SA, Wang L, Woo M.

Lab Invest. 2011 Apr;91(4):527-38. doi: 10.1038/labinvest.2010.207. Epub 2011 Jan 17.

8.

Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death.

Kucejova B, Sunny NE, Nguyen AD, Hallac R, Fu X, Peña-Llopis S, Mason RP, Deberardinis RJ, Xie XJ, Debose-Boyd R, Kodibagkar VD, Burgess SC, Brugarolas J.

Oncogene. 2011 May 5;30(18):2147-60. doi: 10.1038/onc.2010.587. Epub 2011 Jan 10.

9.

Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.

Karam JA, Zhang XY, Tamboli P, Margulis V, Wang H, Abel EJ, Culp SH, Wood CG.

Eur Urol. 2011 Apr;59(4):619-28. doi: 10.1016/j.eururo.2010.11.043. Epub 2010 Dec 8.

PMID:
21167632
10.

Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL.

Li M, Kim WY.

J Cell Mol Med. 2011 Feb;15(2):187-95. doi: 10.1111/j.1582-4934.2010.01238.x. Review.

11.

Brick1 is an essential regulator of actin cytoskeleton required for embryonic development and cell transformation.

Escobar B, de Cárcer G, Fernández-Miranda G, Cascón A, Bravo-Cordero JJ, Montoya MC, Robledo M, Cañamero M, Malumbres M.

Cancer Res. 2010 Nov 15;70(22):9349-59. doi: 10.1158/0008-5472.CAN-09-4491. Epub 2010 Sep 22.

12.
13.

Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina.

Weidemann A, Krohne TU, Aguilar E, Kurihara T, Takeda N, Dorrell MI, Simon MC, Haase VH, Friedlander M, Johnson RS.

Glia. 2010 Aug;58(10):1177-85. doi: 10.1002/glia.20997.

14.

Deletion of von Hippel-Lindau in glomerular podocytes results in glomerular basement membrane thickening, ectopic subepithelial deposition of collagen {alpha}1{alpha}2{alpha}1(IV), expression of neuroglobin, and proteinuria.

Steenhard BM, Isom K, Stroganova L, St John PL, Zelenchuk A, Freeburg PB, Holzman LB, Abrahamson DR.

Am J Pathol. 2010 Jul;177(1):84-96. doi: 10.2353/ajpath.2010.090767. Epub 2010 Jun 3.

15.

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.

Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R.

Mol Cancer Ther. 2010 Jun;9(6):1525-35. doi: 10.1158/1535-7163.MCT-09-1106. Epub 2010 May 25.

16.

Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma.

Pei J, Feder MM, Al-Saleem T, Liu Z, Liu A, Hudes GR, Uzzo RG, Testa JR.

Genes Chromosomes Cancer. 2010 Jul;49(7):610-9. doi: 10.1002/gcc.20771.

17.

VHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis.

Seagroves TN, Peacock DL, Liao D, Schwab LP, Krueger R, Handorf CR, Haase VH, Johnson RS.

Am J Pathol. 2010 May;176(5):2269-82. doi: 10.2353/ajpath.2010.090310. Epub 2010 Apr 9.

18.

Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype.

Mettu P, Agrón E, Samtani S, Chew EY, Wong WT.

Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4464-70. doi: 10.1167/iovs.10-5223. Epub 2010 Apr 7.

19.

von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish.

van Rooijen E, Voest EE, Logister I, Bussmann J, Korving J, van Eeden FJ, Giles RH, Schulte-Merker S.

Dis Model Mech. 2010 May-Jun;3(5-6):343-53. doi: 10.1242/dmm.004036. Epub 2010 Mar 24.

20.

The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.

Clark PE.

Kidney Int. 2009 Nov;76(9):939-45. doi: 10.1038/ki.2009.296. Epub 2009 Aug 5. Review.

Items per page

Supplemental Content

Write to the Help Desk